Biogen Inc. is rated a Buy, as Leqembi Q3 sales rise 66.9% year over year to $202 million and progression risk falls 49% versus ADNI.
Biogen: Why I’m Still Bullish Despite Market Turmoil
view original post
Biogen Inc. is rated a Buy, as Leqembi Q3 sales rise 66.9% year over year to $202 million and progression risk falls 49% versus ADNI.